Putri Utari Mudhia Arisa, Raharja Putu Angga Risky, Situmorang Gerhard Reinaldi, Wahyudi Irfan, Rodjani Arry, Puspitasari Henny Adriani, Imam Abubakr, Saraiva Luis R, Vallasciani Santiago, Abbas Tariq O
Urology Department, Cipto Mangunkusumo Hospital/Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Pediatric Nephrology Division, Sidra Medicine, Doha, Qatar.
Front Pediatr. 2025 Aug 26;13:1621716. doi: 10.3389/fped.2025.1621716. eCollection 2025.
Vesicoureteral reflux (VUR) is a prevalent pediatric urological condition that increases children's risk of urinary tract infections (UTIs) and renal damage. Renal scarring linked to VUR can lead to long-term complications, including hypertension and chronic kidney disease (CKD). Although traditional imaging techniques, such as dimercaptosuccinic acid (DMSA) scans, are regarded as the gold standard for identifying renal scarring, they come with risks of radiation exposure and high costs. This review investigates the diagnostic accuracy of blood and urine biomarkers as alternative methods for detecting renal scarring in VUR.
This systematic review adhered to the PRISMA 2020 guidelines. We conducted a comprehensive search across three databases-PubMed, ScienceDirect, and Cochrane-for studies on biomarkers associated with renal scarring in children with VUR. The included studies were evaluated for diagnostic accuracy (sensitivity and specificity) and assessed for risk of bias using the QUADAS-2 framework.
Nine studies met the eligibility criteria and were included in the qualitative synthesis. Biomarkers such as NGAL, CRP, CXCL8/IL-8, LL-37, and IL-6 were evaluated. Among these, urinary NGAL demonstrated the best diagnostic performance, with sensitivity ranging from 72%-84% and specificity between 60% and 81%. Other biomarkers exhibited moderate accuracy, although they were less reliable than NGAL. Overall, biomarkers present a promising non-invasive alternative to traditional imaging for detecting renal scarring in children with VUR.
Urinary biomarkers, particularly NGAL, hold potential for detecting VUR and renal scarring in children, providing a non-invasive alternative to traditional imaging methods. However, additional validation and standardization are necessary before these biomarkers can be routinely applied in clinical practice.
膀胱输尿管反流(VUR)是一种常见的儿科泌尿系统疾病,会增加儿童患尿路感染(UTIs)和肾损伤的风险。与VUR相关的肾瘢痕形成可导致长期并发症,包括高血压和慢性肾脏病(CKD)。尽管传统成像技术,如二巯基丁二酸(DMSA)扫描,被视为识别肾瘢痕形成的金标准,但它们存在辐射暴露风险和高成本。本综述调查了血液和尿液生物标志物作为检测VUR中肾瘢痕形成的替代方法的诊断准确性。
本系统综述遵循PRISMA 2020指南。我们在三个数据库——PubMed、ScienceDirect和Cochrane——中进行了全面检索,以查找与VUR患儿肾瘢痕形成相关的生物标志物的研究。对纳入的研究进行诊断准确性(敏感性和特异性)评估,并使用QUADAS-2框架评估偏倚风险。
九项研究符合纳入标准并被纳入定性综合分析。对中性粒细胞明胶酶相关脂质运载蛋白(NGAL)、C反应蛋白(CRP)、CXC趋化因子配体8/白细胞介素8(CXCL8/IL-8)、抗菌肽LL-37和白细胞介素6(IL-6)等生物标志物进行了评估。其中,尿NGAL表现出最佳的诊断性能,敏感性范围为72%-84%,特异性在60%至81%之间。其他生物标志物表现出中等准确性,尽管它们不如NGAL可靠。总体而言,生物标志物为检测VUR患儿的肾瘢痕形成提供了一种有前景的非侵入性替代传统成像的方法。
尿液生物标志物,尤其是NGAL,在检测儿童VUR和肾瘢痕形成方面具有潜力,为传统成像方法提供了一种非侵入性替代方法。然而,在这些生物标志物能够常规应用于临床实践之前,还需要进一步的验证和标准化。